Liu Wei's BioMap Bet: From 400 Startup Checks to Building Biology's AI Engine

Liu Wei spent nearly two decades writing cheques for other people's ideas. Now he is writing code, hiring scientists and building a company of his own. For anyone tracking where Asia's smartest technology money is moving, that switch — from backer to operator — is the signal worth watching.

The facts are these. Wei spent 18 years as an early-stage investor, including a stint as general partner at Legend Star Ventures and as founding CEO of Baidu Ventures. Over that career he invested in and incubated more than 400 early-stage technology companies worldwide, and more than 50 of those were focused on artificial intelligence for the life sciences. Today he is co-founder and CEO of BioMap, a company built around the premise that AI can be applied to biology at scale.

To understand why this matters, you need the local context. Legend Star sits inside the Legend Holdings orbit, the Chinese conglomerate best known for nurturing Lenovo; Baidu Ventures was the corporate venture arm of Baidu, one of China's original internet giants. Those are not anonymous cheque-writers. They are institutions that shaped how China's technology ecosystem learned to take risk. Wei was in the room early, backing AI companies when the phrase was still a research-lab curiosity rather than a boardroom budget line. In China's venture world, that kind of longevity buys something rarer than capital: pattern recognition. Wei has watched hundreds of teams fail and a handful compound. He has seen which founders survive the trough between a promising demo and a paying customer.

The pivot toward biology is not random. AI for life sciences has become one of the few corners of technology where the funding cycle has not fully cooled. Drug discovery is slow, expensive and littered with failure, which makes it an irresistible target for anyone selling computational efficiency. In the United States, the template was set by companies that paired machine learning with laboratory automation. In China, the same thesis has attracted a mix of internet veterans, pharmaceutical incumbents and government-backed funds. Wei's track record — more than 50 AI-for-life-sciences bets before he ever ran one himself — gives him a founder's credibility that most first-time biotech CEOs lack. He is not learning the sector from a pitch deck.

What does this say about Asian capital more broadly? It says the region's most experienced technology investors are no longer content to sit on the sidelines of the industries they helped finance. The first generation of Chinese internet investors made their names picking platforms. The next move is deeper into science — biology, materials, energy — where the timelines are longer and the returns, if they come, are less about user growth and more about intellectual property. Wei's transition also reflects a maturing ecosystem: when the best investors start founding companies, it usually means they believe the opportunity is too large to outsource. That is a vote of confidence in the underlying science, and a warning to rivals that the competition for talent just got sharper.

BioMap's success is not guaranteed. Biology is not software; experiments fail for reasons no model can predict, and regulatory pathways are slow. But the direction of travel is clear. The people who spent the last decade financing Asia's AI boom are now rolling up their sleeves and building in it. Wei's second act will be judged not by how many companies he backed, but by whether one he runs can turn computation into cures. For the wealth watchers of Asia, that is the number to track next.